A1 Refereed original research article in a scientific journal
Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimer's disease
Authors: Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chetelat G, Oliveira CR, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, Buchem MA, Cavedo E, Chen K, Cohen AD, Foerster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, Laere K, Leon MJ, Maier W, Marcusson J, Meulenbroek O, Mollergard HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodriguez-Rodriguez E, Roe CM, Ruther E, Santana I, Schroder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, Doorn LJCVW, Waldemar G, Wallin AK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sanchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, Berckel BNM, Flier WMD, Scheltens P, Visser PJ, Ossenkoppele R, Scheltens P, Flier WMD, Ossenkoppele R, Visser PJ, Berckel BNM
Publisher: ELSEVIER SCIENCE INC
Publication year: 2018
Journal: Alzheimer's and Dementia
Journal name in source: ALZHEIMERS & DEMENTIA
Journal acronym: ALZHEIMERS DEMENT
Volume: 14
Issue: 7
First page : 913
Last page: 924
Number of pages: 12
ISSN: 1552-5260
DOI: https://doi.org/10.1016/j.jalz.2018.02.009
Introduction: Apolipoprotein E (APOE) epsilon 4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid beta(A beta) pathology. Methods: We included 3451 A beta+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE epsilon 4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE epsilon 4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in A beta+ cognitively normal and A beta+ mild cognitive impairment (P <.05) but not in A beta+ AD dementia (P =.66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE E4 prevalence in AD was higher than that in previous studies, which did not require presence of A beta pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
